摘要
乳腺癌是女性最好发的恶性肿瘤之一,常规治疗方法虽取得了一定的疗效,但仍存在局限性。细胞分裂周期蛋白42(cell division cycle 42,Cdc42)是一种Rho家族蛋白的小GTP酶,可与GTP结合而被激活,进一步调控细胞骨架变化、极性建立、运动和迁移等各种生理进程。越来越多的研究表明,Cdc42在乳腺癌发生、发展过程中具有重要的调控作用,提示Cdc42有望作为一个新的治疗靶点应用到乳腺癌临床治疗中。该文总结最新的研究成果,探讨Cdc42在乳腺癌细胞极性建立、伪足形成中的作用,同时阐述Cdc42调控乳腺癌细胞侵袭、迁移和远处转移的具体分子机制以及相关的信号通路与乳腺癌演进的密切联系,并提出针对Cdc42的靶向治疗方法,为乳腺癌的治疗提供了新思路。
Breast cancer is one of the most common malignant tumors in women. Although the conventional treatment has demonstrated a certain effect, there are still some limitations. Cdc42（cell division cycle 42） is a kind of small GTP enzyme of Rho family which can be activated via combining with GTP, resulting in effects on various physiological processes such as cytoskeletal changes, polarity establishment, movement and migration. More and more studies show that Cdc42 plays an important role during the genesis and development of breast cancer, suggesting that Cdc42 may serve as a new therapeutic target for breast cancer clinical therapy. This review discussed the role of Cdc42 in the polarity establishment, pseudopod formation of breast cancer cells as well the molecular mechanism of invasion, migration and metastasis. Cdc42-mediated signaling pathway involving breast cancer evolution also be described. Most importantly, we put forward a perspective on Cdc42-targed therapeutic method, providing a new idea for the treatment of breast cancer.
作者
李君
张煜
陈厚文
熊丽霞
Li Jun;Zhang Yu;Chen Houwen;Xiong Lixia(Department of Pathophysiology,Basic Medical College,Nanchang University,Nanchang 330006,China;Second Clinical Medical College,Nanchang University,Nanchang 330006,China;First Clinical Medical College,Nanchang UniversitY,Nanchang 330006,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2018年第7期1223-1230,共8页
Chinese Journal of Cell Biology
基金
国家自然科学基金(批准号:31660287)资助的课题~~
